Form 8-K - Current report:
SEC Accession No. 0001213900-25-041063
Filing Date
2025-05-08
Accepted
2025-05-08 16:10:21
Documents
15
Period of Report
2025-05-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241411-8k_cero.htm   iXBRL 8-K 40675
2 PRESS RELEASE OF CERO THERAPEUTICS HOLDINGS, INC., DATED MAY 8, 2025 ea024141101ex99-1_cero.htm EX-99.1 11218
  Complete submission text file 0001213900-25-041063.txt   275439

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20250507.xsd EX-101.SCH 3815
4 XBRL DEFINITION FILE cero-20250507_def.xml EX-101.DEF 26699
5 XBRL LABEL FILE cero-20250507_lab.xml EX-101.LAB 36874
6 XBRL PRESENTATION FILE cero-20250507_pre.xml EX-101.PRE 25323
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0241411-8k_cero_htm.xml XML 5827
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 25926148
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)